Q&A With Jon Leibowitz, FTC Chairman
Q: What will your agency's enforcement priorities be over the next few years?
A: On the competition side, our top priority is stopping anti-competitive agreements between branded and generic pharmaceutical companies. We’ve estimated that these pay-for-delay deals cost consumers $3.5 billion a year by keeping lower-cost generics off the market. We will continue to challenge these sweetheart deals in court, where we...
To view the full article, register now.